Tyra Biosciences IncNASDAQ:TYRA
- LAST PRICE16.1100
- TODAY'S CHANGE (%)-1.0400 (-6.0641%)
- Bid / Lots15.0000/ 1
- Ask / Lots17.2900/ 1
- Open / Previous Close16.6900 / 17.1500
- Day Range
- 52 Week Range
- Volume227,744
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TYRA |
|---|---|---|
| 09:32 ET | 4019 | 16.31 |
| 09:33 ET | 100 | 16.4864 |
| 09:39 ET | 6598 | 16.68 |
| 09:42 ET | 2500 | 16.835 |
| 09:48 ET | 8700 | 16.81 |
| 09:50 ET | 500 | 16.81 |
| 09:51 ET | 1500 | 16.815 |
| 09:53 ET | 500 | 16.87 |
| 10:04 ET | 581 | 16.785 |
| 10:06 ET | 530 | 16.64 |
| 10:08 ET | 194 | 16.44 |
| 10:09 ET | 500 | 16.32 |
| 10:11 ET | 827 | 16.42 |
| 10:13 ET | 200 | 16.58 |
| 10:18 ET | 185 | 16.5995 |
| 10:26 ET | 400 | 16.46 |
| 10:29 ET | 540 | 16.44 |
| 10:31 ET | 325 | 16.423 |
| 10:33 ET | 800 | 16.51 |
| 10:36 ET | 4047 | 16.46 |
| 10:38 ET | 200 | 16.535 |
| 10:40 ET | 275 | 16.695 |
| 10:42 ET | 1000 | 16.765 |
| 10:44 ET | 100 | 16.85 |
| 10:45 ET | 1800 | 16.77 |
| 10:47 ET | 641 | 16.71 |
| 10:51 ET | 100 | 16.77 |
| 10:54 ET | 100 | 16.81 |
| 11:00 ET | 1500 | 16.675 |
| 11:02 ET | 300 | 16.665 |
| 11:03 ET | 600 | 16.59 |
| 11:07 ET | 100 | 16.65 |
| 11:09 ET | 200 | 16.59 |
| 11:12 ET | 300 | 16.54 |
| 11:14 ET | 600 | 16.545 |
| 11:16 ET | 100 | 16.545 |
| 11:25 ET | 100 | 16.6 |
| 11:27 ET | 400 | 16.52 |
| 11:38 ET | 772 | 16.51 |
| 11:39 ET | 601 | 16.6 |
| 11:41 ET | 898 | 16.635 |
| 11:50 ET | 100 | 16.6 |
| 11:59 ET | 900 | 16.64 |
| 12:01 ET | 600 | 16.59 |
| 12:03 ET | 700 | 16.53 |
| 12:06 ET | 600 | 16.45 |
| 12:08 ET | 300 | 16.425 |
| 12:14 ET | 1530 | 16.5 |
| 12:15 ET | 100 | 16.515 |
| 12:17 ET | 600 | 16.47 |
| 12:19 ET | 600 | 16.52 |
| 12:21 ET | 200 | 16.575 |
| 12:24 ET | 8793 | 16.28 |
| 12:33 ET | 100 | 16.35 |
| 12:35 ET | 816 | 16.48 |
| 12:42 ET | 300 | 16.52 |
| 12:44 ET | 117 | 16.51 |
| 12:48 ET | 300 | 16.51 |
| 12:50 ET | 944 | 16.51 |
| 12:53 ET | 4984 | 16.29 |
| 12:57 ET | 300 | 16.175 |
| 01:00 ET | 200 | 16.14 |
| 01:04 ET | 100 | 16.09 |
| 01:06 ET | 228 | 16.06 |
| 01:08 ET | 300 | 16.05 |
| 01:09 ET | 7884 | 16.16 |
| 01:11 ET | 100 | 16.13 |
| 01:18 ET | 700 | 16.03 |
| 01:20 ET | 300 | 16.08 |
| 01:24 ET | 1100 | 15.96 |
| 01:26 ET | 100 | 15.97 |
| 01:27 ET | 500 | 15.97 |
| 01:31 ET | 200 | 15.8409 |
| 01:36 ET | 655 | 15.91 |
| 01:38 ET | 100 | 16 |
| 01:45 ET | 900 | 16.08 |
| 01:49 ET | 301 | 16.1 |
| 01:51 ET | 320 | 16.075 |
| 01:54 ET | 491 | 16.17 |
| 01:56 ET | 343 | 16.22 |
| 01:58 ET | 2382 | 16.37 |
| 02:00 ET | 800 | 16.4 |
| 02:02 ET | 2406 | 16.29 |
| 02:03 ET | 200 | 16.255 |
| 02:07 ET | 100 | 16.245 |
| 02:09 ET | 1237 | 16.264 |
| 02:12 ET | 400 | 16.27 |
| 02:14 ET | 100 | 16.29 |
| 02:16 ET | 300 | 16.285 |
| 02:18 ET | 500 | 16.29 |
| 02:20 ET | 3400 | 16.29 |
| 02:21 ET | 600 | 16.29 |
| 02:23 ET | 200 | 16.29 |
| 02:25 ET | 1232 | 16.17 |
| 02:27 ET | 1740 | 16.08 |
| 02:32 ET | 100 | 16.115 |
| 02:34 ET | 1224 | 16.2 |
| 02:38 ET | 300 | 16.237 |
| 02:39 ET | 330 | 16.195 |
| 02:45 ET | 100 | 16.16 |
| 02:52 ET | 400 | 16.2 |
| 02:54 ET | 200 | 16.24 |
| 02:56 ET | 527 | 16.175 |
| 02:57 ET | 800 | 16.12 |
| 03:01 ET | 418 | 16.06 |
| 03:06 ET | 300 | 16.06 |
| 03:08 ET | 100 | 16.085 |
| 03:12 ET | 100 | 16.07 |
| 03:14 ET | 100 | 16.06 |
| 03:15 ET | 300 | 16.06 |
| 03:17 ET | 500 | 16.1 |
| 03:19 ET | 400 | 16.05 |
| 03:21 ET | 221 | 16.02 |
| 03:24 ET | 400 | 15.98 |
| 03:28 ET | 2702 | 16.01 |
| 03:30 ET | 100 | 16 |
| 03:32 ET | 300 | 16 |
| 03:33 ET | 116 | 16.005 |
| 03:35 ET | 200 | 15.991 |
| 03:37 ET | 504 | 16.05 |
| 03:42 ET | 300 | 16.09 |
| 03:44 ET | 100 | 16.08 |
| 03:46 ET | 2256 | 16.09 |
| 03:48 ET | 3056 | 16.15 |
| 03:50 ET | 436 | 16.045 |
| 03:51 ET | 678 | 16.06 |
| 03:53 ET | 2000 | 16.08 |
| 03:55 ET | 680 | 16.07 |
| 03:57 ET | 1526 | 16.04 |
| 04:00 ET | 30048 | 16.11 |
Nov 7, 2024
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 29, 2024
DJ Tyra Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co., from 6:35AM ET on Tuesday Oct 29, 2024 by Dow Jones
6:35AM ET on Tuesday Oct 29, 2024 by Dow Jones
Oct 28, 2024
DJ Tyra Biosciences Is Maintained at Buy by HC Wainwright & Co., from 8:29AM ET on Monday Oct 28, 2024 by Dow Jones
8:29AM ET on Monday Oct 28, 2024 by Dow JonesTyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301), from 7:00AM ET on Monday Oct 28, 2024 by Dow Jones
7:00AM ET on Monday Oct 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tyra Biosciences Inc | 850.7M | -9.5x | --- |
Replimune Group Inc | 849.9M | -3.8x | --- |
Dianthus Therapeutics Inc | 853.4M | -5.2x | --- |
Neurogene Inc | 886.3M | -13.8x | --- |
Erasca Inc | 887.1M | -3.4x | --- |
Anavex Life Sciences Corp | 783.5M | -18.4x | --- |
Company Information
Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.
Contact Information
- Headquarters
- 2656 State StreetCARLSBAD, CA, United States 92008
- Phone
- 619-728-4760
- Fax
- 302-655-5049
Executives
- Non-Executive Chairman of the Board
- Robert More
- President, Chief Executive Officer, Treasurer, Director
- Todd Harris
- Chief Financial Officer
- Alan Fuhrman
- Chief Operating Officer
- Daniel Bensen
- Chief Medical Officer
- Douglas Warner
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $850.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.69 |
Book Value | $4.75 |
P/E Ratio | -9.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
